We're starting positions in 2 more defensive stocks to balance our AI exposure

The article initiates two new portfolio positions: BNY (240 shares at ~$161) and Kimberly-Clark (365 shares at ~$108), targeting ~$180 for BNY (17.5x 2027E EPS) and ~$120 for KMB (16x 2027E EPS). The manager cites a defensive tilt ahead of a potential September Fed hike (higher discount rates compress P/Es) and argues BNY’s fee-based model limits exposure to the credit cycle, while KMB’s pending Kenvue deal (expected to close before year-end) adds scale plus $1.9B cost synergies and a ~4.75% dividend yield.

Analysis

The real signal is factor rotation, not the individual names: the portfolio is trading away long-duration AI capex exposure and into cash-flow compounding with lower earnings beta. That tends to help asset-light financial infrastructure like BNY more than traditional lenders, because the market can re-rate fee stability without needing a steepening yield curve or loan growth. BK is the closest competitive watch item: if BNY keeps taking operating leverage out of custody/clearing, the sector may bifurcate toward the best execution and away from the balance-sheet banks.

For BNY, the near-term setup is less about a rate hike itself than about investors paying up for visible mid-teens EPS growth and margin discipline while deposit franchises get compressed elsewhere. The risk is that this becomes a crowded defensives trade; if the Fed blinks or equity volumes/asset values soften, the market could rotate back into cyclicals and leave BNY’s multiple stuck. A break below the low-$150s would likely signal the market is no longer rewarding quality/defensiveness.

KMB is a different story: the catalyst is not the dividend but whether the Kenvue deal converts a mature staples compounder into a higher-quality health-and-wellness platform. The market is likely underpricing integration friction, litigation noise, and the balance-sheet drag needed to fund the transaction; that means the rerating may be slower than headline synergies imply. If management does not show clear cost takeout and leverage reduction within 1-2 quarters post-close, the valuation gap to PG may persist or widen.

Key Decisions for Investors

• Long BNY / short WFC for 1-3 months into the Fed meeting: express the view that fee-based custody/asset servicing outperforms deposit-beta banks in a higher-rate, lower-multiple regime. Falsifier: a dovish pivot or sharp curve steepening that re-accelerates WFC NII expectations.
• Buy KMB on weakness or use a 3-6 month call spread; the upside is a modest multiple rerate if synergy delivery is credible, but the position should be sized for slower realization. Falsifier: deal financing/leverage comes in meaningfully worse than expected or litigation headlines intensify.
• Pair trade: long KMB / short PG into the first post-close update if KMB can show faster earnings growth from Kenvue than the market is modeling. Risk/reward is attractive only if KMB demonstrates integration progress; otherwise PG remains the cleaner quality staple.
• Set an alert on BNY if it loses its premium multiple despite stable earnings revisions; that would be the signal that the defensive rotation has become overextended and the entry point is no longer favorable.